Health Canada Approves Lynparza in Combination with Abiraterone and Prednisone or Prednisolone for Patients with BRCA Mutated Metastatic Castration-Resistant Prostate Cancer

Health Canada has granted conditional approval for the use of Lynparza in combination with abiraterone and prednisone or prednisolone to treat patients with BRCA mutated metastatic castration-resistant prostate cancer. This exciting development is based on the promising results from the Phase 3 PROpel trial, which demonstrated that patients receiving Lynparza/abiraterone experienced improved rad..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 14.
  • textsms

Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada

Femasys Inc. has received approval from Health Canada for its FemCath intrauterine catheter, which is the first device to allow selective evaluation of fallopian tubes with contrast in the country. The product works together with Femasys' FemVue ultrasound-based diagnostic test as part of an infertility assessment before any therapeutic options can be considered, such as artificial insemination ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 9.
  • textsms

Roche's Cerebrospinal Fluid Assays Approved in Canada for Alzheimer's Diagnosis

Roche Diagnostics Corporation has gained approval from Health Canada for its Cerebrospinal Fluid (CSF) assays to measure three biomarkers in adults aged 55 and over, allowing physicians to diagnose Alzheimer's disease. The Elecsys® beta-Amyloid, Phospho-Tau(181P), and Total-Tau CSF tests can be carried out on automated immunoassay analyzers available across the country. These biomarkers help tra..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 9.
  • textsms